Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
Lyell Immunopharma Inc (NASDAQ: LYEL) closed the day trading at $0.57 down -1.15% from the previous closing price of $0.58. In other words, the price has decreased by -$1.15 from its previous closing price. On the day, 0.88 million shares were traded. LYEL stock price reached its highest trading level at $0.61 during the session, while it also had its lowest trading level at $0.5682.
Ratios:
For a better understanding of LYEL, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 13.43 and its Current Ratio is at 13.43. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.10.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, BofA Securities on October 30, 2024, Downgraded its rating to Underperform and sets its target price to $1 from $6 previously.
On June 27, 2024, H.C. Wainwright Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $6 to $1.
JP Morgan Downgraded its Overweight to Neutral on August 28, 2023, whereas the target price for the stock was revised from $15 to $5.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LYEL now has a Market Capitalization of 166210944 and an Enterprise Value of -223123392. For the stock, the TTM Price-to-Sale (P/S) ratio is 2770.20 while its Price-to-Book (P/B) ratio in mrq is 0.28. Its current Enterprise Value per Revenue stands at -3541.641 whereas that against EBITDA is 1.135.
Stock Price History:
Over the past 52 weeks, LYEL has reached a high of $3.26, while it has fallen to a 52-week low of $0.55. The 50-Day Moving Average of the stock is -31.59%, while the 200-Day Moving Average is calculated to be -63.12%.
Shares Statistics:
Over the past 3-months, LYEL traded about 1.54M shares per day on average, while over the past 10 days, LYEL traded about 856920 shares per day. A total of 256.56M shares are outstanding, with a floating share count of 150.81M. Insiders hold about 48.38% of the company’s shares, while institutions hold 21.62% stake in the company. Shares short for LYEL as of 1735603200 were 12314391 with a Short Ratio of 8.01, compared to 1732838400 on 9451540. Therefore, it implies a Short% of Shares Outstanding of 12314391 and a Short% of Float of 5.6900002.
Earnings Estimates
The stock of Lyell Immunopharma Inc (LYEL) is currently drawing attention from 1.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between -$0.58 and -$0.58 for the fiscal current year, implying an average EPS of -$0.58. EPS for the following year is -$0.45, with 1.0 analysts recommending between -$0.45 and -$0.45.
Revenue Estimates
A total of 4 analysts have provided revenue estimates for LYEL’s current fiscal year. The highest revenue estimate was $130k, while the lowest revenue estimate was $16k, resulting in an average revenue estimate of $53k. In the same quarter a year ago, actual revenue was $130k
